June 1 | 2021 Management exercise all warrants within the framework of the 2018 incentive program Read more
May 11 | 2021 Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million. Read more
May 11 | 2021 Teckningsoptioner av serie TO1 tecknades till cirka 96,75 procent och 2cureX AB tillförs cirka 31,40 MSEK Read more
May 5 | 2021 Sista dag för handel med teckningsoptionerna av serie TO1 i 2cureX AB är idag, den 5 maj 2021 Read more
April 24 | 2021 Correction of “Notice to attend the Annual General Meeting of 2cureX AB” issued on 23[rd] April 2021. Read more
April 24 | 2021 Korrektion till ”Kallelse till årsstämma i 2cureX AB” utfärdad den 23 april 2021. Read more
April 23 | 2021 Teckningskursen för utnyttjande av teckningsoptioner av serie TO1 i 2cureX AB har fastställts till 13,22 SEK och teckningsperioden inleds den 26 april 2021 Read more
April 23 | 2021 The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021 Read more
March 1 | 2021 2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint. Read more